Covalon Technologies Ltd. (COV.V)
CAD 3.44
(2.99%)
CAD 3.44
(2.99%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.1 Million CAD | -0.68% |
| 2022 | 6.14 Million CAD | -14.68% |
| 2021 | 7.2 Million CAD | -71.83% |
| 2020 | 25.59 Million CAD | 3.7% |
| 2019 | 24.67 Million CAD | 274.85% |
| 2018 | 6.58 Million CAD | 120.47% |
| 2017 | 2.98 Million CAD | 11.38% |
| 2016 | 2.68 Million CAD | -5.76% |
| 2015 | 2.84 Million CAD | 16.88% |
| 2014 | 2.43 Million CAD | -10.65% |
| 2013 | 2.72 Million CAD | -0.19% |
| 2012 | 2.72 Million CAD | 18.31% |
| 2011 | 2.3 Million CAD | -16.1% |
| 2010 | 2.74 Million CAD | 42.76% |
| 2009 | 1.92 Million CAD | -15.43% |
| 2008 | 2.27 Million CAD | -14.1% |
| 2007 | 2.65 Million CAD | 402.67% |
| 2006 | 527.43 Thousand CAD | -25.49% |
| 2005 | 707.83 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 4.85 Million CAD | 38.64% |
| 2024 Q2 | 3.49 Million CAD | -24.18% |
| 2024 Q1 | 4.61 Million CAD | -24.42% |
| 2023 Q1 | 6.54 Million CAD | 6.4% |
| 2023 Q2 | 5.75 Million CAD | -11.98% |
| 2023 Q3 | 5.33 Million CAD | -7.42% |
| 2023 FY | 6.1 Million CAD | -0.68% |
| 2023 Q4 | 6.1 Million CAD | 14.56% |
| 2022 FY | 6.14 Million CAD | -14.68% |
| 2022 Q2 | 5.35 Million CAD | -12.15% |
| 2022 Q3 | 4.61 Million CAD | -13.87% |
| 2022 Q1 | 6.1 Million CAD | -15.36% |
| 2022 Q4 | 6.14 Million CAD | 33.22% |
| 2021 Q4 | 7.2 Million CAD | -70.42% |
| 2021 Q1 | 24.14 Million CAD | -5.65% |
| 2021 Q2 | 24.9 Million CAD | 3.13% |
| 2021 Q3 | 24.36 Million CAD | -2.14% |
| 2021 FY | 7.2 Million CAD | -71.83% |
| 2020 Q3 | 26.86 Million CAD | -0.13% |
| 2020 Q2 | 26.9 Million CAD | 5.34% |
| 2020 FY | 25.59 Million CAD | 3.7% |
| 2020 Q1 | 25.53 Million CAD | 3.49% |
| 2020 Q4 | 25.59 Million CAD | -4.75% |
| 2019 Q3 | 23.94 Million CAD | -4.6% |
| 2019 FY | 24.67 Million CAD | 274.85% |
| 2019 Q2 | 25.09 Million CAD | 2.65% |
| 2019 Q1 | 24.44 Million CAD | 271.38% |
| 2019 Q4 | 24.67 Million CAD | 3.06% |
| 2018 Q3 | 2.97 Million CAD | 2.6% |
| 2018 Q1 | 3.01 Million CAD | 0.93% |
| 2018 FY | 6.58 Million CAD | 120.47% |
| 2018 Q4 | 6.58 Million CAD | 120.93% |
| 2018 Q2 | 2.9 Million CAD | -3.64% |
| 2017 Q1 | 2.49 Million CAD | -7.09% |
| 2017 FY | 2.98 Million CAD | 11.38% |
| 2017 Q4 | 2.98 Million CAD | 7.66% |
| 2017 Q3 | 2.77 Million CAD | -10.95% |
| 2017 Q2 | 3.11 Million CAD | 25.04% |
| 2016 Q3 | 2.69 Million CAD | -29.1% |
| 2016 Q2 | 3.8 Million CAD | 6.73% |
| 2016 Q4 | 2.68 Million CAD | -0.54% |
| 2016 FY | 2.68 Million CAD | -5.76% |
| 2016 Q1 | 3.56 Million CAD | 25.2% |
| 2015 Q1 | 2.68 Million CAD | 10.16% |
| 2015 Q4 | 2.84 Million CAD | 3.2% |
| 2015 FY | 2.84 Million CAD | 16.88% |
| 2015 Q2 | 2.89 Million CAD | 7.99% |
| 2015 Q3 | 2.75 Million CAD | -4.79% |
| 2014 FY | 2.43 Million CAD | -10.65% |
| 2014 Q1 | 3.09 Million CAD | 13.74% |
| 2014 Q3 | 2.82 Million CAD | -2.78% |
| 2014 Q4 | 2.43 Million CAD | -13.94% |
| 2014 Q2 | 2.9 Million CAD | -6.11% |
| 2013 Q1 | 2.36 Million CAD | -13.19% |
| 2013 Q4 | 2.72 Million CAD | -5.09% |
| 2013 FY | 2.72 Million CAD | -0.19% |
| 2013 Q3 | 2.86 Million CAD | 7.89% |
| 2013 Q2 | 2.66 Million CAD | 12.27% |
| 2012 Q3 | 2.29 Million CAD | -2.28% |
| 2012 Q2 | 2.35 Million CAD | 3.01% |
| 2012 Q1 | 2.28 Million CAD | -0.97% |
| 2012 FY | 2.72 Million CAD | 18.31% |
| 2012 Q4 | 2.72 Million CAD | 18.68% |
| 2011 FY | 2.3 Million CAD | -16.1% |
| 2011 Q4 | 2.3 Million CAD | 40.34% |
| 2011 Q3 | 1.64 Million CAD | 4.34% |
| 2011 Q2 | 1.57 Million CAD | -30.64% |
| 2011 Q1 | 2.27 Million CAD | -17.4% |
| 2010 Q3 | 3.29 Million CAD | 106.38% |
| 2010 Q4 | 2.74 Million CAD | -16.56% |
| 2010 FY | 2.74 Million CAD | 42.76% |
| 2010 Q1 | 1.65 Million CAD | -13.84% |
| 2010 Q2 | 1.59 Million CAD | -3.78% |
| 2009 Q4 | 1.92 Million CAD | -10.15% |
| 2009 Q3 | 2.14 Million CAD | -14.43% |
| 2009 Q2 | 2.5 Million CAD | -0.07% |
| 2009 Q1 | 2.5 Million CAD | 10.06% |
| 2009 FY | 1.92 Million CAD | -15.43% |
| 2008 Q2 | 2.2 Million CAD | -6.77% |
| 2008 Q4 | 2.27 Million CAD | 13.15% |
| 2008 Q3 | 2.01 Million CAD | -8.62% |
| 2008 FY | 2.27 Million CAD | -14.1% |
| 2008 Q1 | 2.36 Million CAD | -10.88% |
| 2007 Q3 | 2.67 Million CAD | -4.74% |
| 2007 FY | 2.65 Million CAD | 402.67% |
| 2007 Q1 | 589.38 Thousand CAD | 11.75% |
| 2007 Q4 | 2.65 Million CAD | -1.05% |
| 2007 Q2 | 2.81 Million CAD | 377.2% |
| 2006 Q3 | 523.76 Thousand CAD | -21.38% |
| 2006 Q2 | 666.21 Thousand CAD | -24.66% |
| 2006 Q1 | 884.23 Thousand CAD | 24.92% |
| 2006 Q4 | 527.43 Thousand CAD | 0.7% |
| 2006 FY | 527.43 Thousand CAD | -25.49% |
| 2005 FY | 707.83 Thousand CAD | 0.0% |
| 2005 Q1 | 1.01 Million CAD | 0.0% |
| 2005 Q2 | 818.59 Thousand CAD | -19.7% |
| 2005 Q4 | 707.83 Thousand CAD | -0.87% |
| 2005 Q3 | 714.02 Thousand CAD | -12.77% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Arch Biopartners Inc. | 6.68 Million CAD | 8.58% |
| Hemostemix Inc. | 7.68 Million CAD | 20.523% |
| Universal Ibogaine Inc. | 2.37 Million CAD | -157.206% |
| Kane Biotech Inc. | 14.09 Million CAD | 56.653% |
| MedMira Inc. | 18.68 Million CAD | 67.309% |
| Marvel Biosciences Corp. | 2.39 Million CAD | -155.291% |
| NervGen Pharma Corp. | 15.24 Million CAD | 59.936% |
| XORTX Therapeutics Inc. | 1.08 Million CAD | -460.819% |